Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth, unlike generics. Eli Lilly's tirzepatide brands also experienced sales growth in the recent period. Doctors prefer innovator semaglutide due to similar pricing and pioneering status. The crowded generic market is causing brands to lose their individual market share.